Vertex Pharmaceuticals already dominates the landscape of treatments for cystic fibrosis, and its position got even better today.
Vertex (NASDAQ: VRTX) said that a cocktail of three of its cystic fibrosis drugs succeeded in two late-stage studies, bolstering the company’s chances to potentially offer a treatment that addresses up to 90 percent of patients who have the debilitating lung disease. Vertex said the data could support the filing of an FDA approval application.
The regimen Vertex reports on today is a combination of an experimental drug, VX-659; and ivacaftor/tezacaftor, the two parts of the already-approved Vertex CF drug sold as… Read more »
UNDERWRITERS AND PARTNERS